Davide Melisi, MD, PhD, discusses INCB161734 and the DAWN-303 trial evaluating the agent in KRAS G12D–mutated metastatic pancreatic ductal adenocarcinoma.
Davide Melisi, MD, PhD
Advertisement
Dr Melisi is an associate professor of medical oncology at the University of Verona in Italy.
Articles by Davide Melisi, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Final Approval to Lutetium Lu 177 Dotatate Biosimilar for SSTR+ GEP-NETs
2
FDA Approves Generic Lanreotide Injection for GEP-NETs
3
FDA Flashback: Breast Cancer Decisions and News From August 2026
4
Tegavivint Plus Osimertinib Shows Early Activity in First-Line EGFR-Mutated NSCLC
5